Abstract
This article explores the pharmacologic rationale for monitoring hourly vital signs and the subsequent effects of disturbances in sleep patterns in the patient who receives a constant infusion of IV NTG. Although some patients may require additional vasoactive drugs to maintain stability of vital signs, this article addresses the monitoring practices for IV NTG in patients with acute MI, unstable angina, or CHF who do not require other vasoactive drugs.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
